fingolimod hydrochloride has been researched along with hydroxyproline in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (hydroxyproline) | Trials (hydroxyproline) | Recent Studies (post-2010) (hydroxyproline) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 10,942 | 334 | 1,426 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Itoh, M; Kataoka, H; Kuno, A; Nakao, H; Ogawa, K; Ohara, H; Okamoto, T; Sano, H; Shirai, T; Tang, M; Yamada, T | 1 |
1 other study(ies) available for fingolimod hydrochloride and hydroxyproline
| Article | Year |
|---|---|
FTY720, an immunosuppressant, attenuates chronic pancreatitis in rats by suppressing T-cell infiltration.
Topics: Animals; Body Weight; Fingolimod Hydrochloride; Hydroxyproline; Immunosuppressive Agents; Interferon-gamma; Male; Organ Size; Pancreas; Pancreatitis, Chronic; Peroxidase; Propylene Glycols; Rats; Rats, Wistar; RNA, Messenger; Sphingosine; T-Lymphocytes; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |